Zedira Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
2ndary - Private
Zedira General Information
Description
Developer of a transglutaminase inhibitor intended to generate homogenous antibody-drug conjugates. The company's biotechnological capabilities include drug discovery programs involving small molecules that block dysregulated transglutaminases and also services for the determination of microbial transglutaminase and research and development, enabling researchers to create specialty reagents and doctors to treat celiac disease patients.
Contact Information
Website
www.zedira.comCorporate Office
- Roesslerstrasse 83
- Hesse
- 64293 Darmstadt
- Germany
Corporate Office
- Roesslerstrasse 83
- Hesse
- 64293 Darmstadt
- Germany
Zedira Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Nov-2023 | Completed | Generating Revenue | |||
| 8. Grant | 30-Nov-2016 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 12-Feb-2015 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 01-Jun-2011 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC | 18-May-2010 | Completed | Startup | |||
| 4. Grant | 02-Jun-2009 | Completed | Startup | |||
| 3. Early Stage VC (Series A) | 01-Sep-2007 | Completed | Startup | |||
| 2. Grant | 04-Jul-2007 | $3.36K | Completed | Startup | ||
| 1. Accelerator/Incubator | 01-Jan-2007 | Completed | Startup |
Zedira Patents
Zedira Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024408031-A1 | Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis | Pending | 22-Dec-2023 | ||
| EP-4637764-A1 | Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis | Pending | 22-Dec-2023 | ||
| WO-2025133265-A1 | Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis | Inactive | 22-Dec-2023 | ||
| WO-2023110138-A1 | Inhibitors of transglutaminases | Inactive | 17-Dec-2021 | ||
| US-20240270715-A1 | Inhibitors of transglutaminases | Pending | 02-Jul-2021 | C07D401/12 |
Zedira Signals
Zedira FAQs
-
When was Zedira founded?
Zedira was founded in 2007.
-
Where is Zedira headquartered?
Zedira is headquartered in Darmstadt, Germany.
-
What is the size of Zedira?
Zedira has 18 total employees.
-
What industry is Zedira in?
Zedira’s primary industry is Drug Discovery.
-
Is Zedira a private or public company?
Zedira is a Private company.
-
What is Zedira’s current revenue?
The current revenue for Zedira is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process